Company: CERO
Filing Date: 2025-01-07
Form Type: 8-K
Source: 0001213900-25-001663
Chunk: 0

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-07
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01 Other Events.

Reference is hereby made to
the Current Report on Form 8-K filed by CERo Therapeutics Holdings, Inc. (the “ Company”) on December 31, 2024, pursuant to
which the Company reported the receipt of proceeds exercises of certain warrants to purchase shares of Series A Preferred Stock and issuances
of shares pursuant to the Company’s committed equity financing facility (the “ Equity Line”) through December 30, 2024.

As a result of the receipt
of such proceeds and the receipt of additional proceeds from sales pursuant to the Equity Line through January 6, 2025, the Company now
reports a cash balance of approximately $5.463 million as of January 7, 2025.

SIGNATURES

Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.

  Date: January 7, 2025      CERO THERAPEUTICS HOLDINGS, INC.                               
 ────────────────────────────────────────────────────────────────────────────────────────────
                             By:                                   /s/ Chris Ehrlich        
                             Name:                                 Chris Ehrlich            
                             Title:                                Chief Executive Officer